These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38757729)

  • 21. Combination therapy with naltrexone and bupropion for obesity.
    Billes SK; Greenway FL
    Expert Opin Pharmacother; 2011 Aug; 12(11):1813-26. PubMed ID: 21689063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
    Fujioka K; Braverman-Panza J
    J Fam Pract; 2016 Jul; 65(7 Suppl):S16-23. PubMed ID: 27565106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.
    Apovian CM
    Future Cardiol; 2016 Mar; 12(2):129-38. PubMed ID: 26679384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obesity Epidemic: Pharmaceutical Weight Loss.
    Curry SA
    R I Med J (2013); 2017 Mar; 100(2):18-20. PubMed ID: 28246654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naltrexone/bupropion for obesity.
    Drug Ther Bull; 2017 Nov; 55(11):126-129. PubMed ID: 29117992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Practical Use of Pharmacotherapy for Obesity.
    Igel LI; Kumar RB; Saunders KH; Aronne LJ
    Gastroenterology; 2017 May; 152(7):1765-1779. PubMed ID: 28192104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity.
    Smith SR; Fujioka K; Gupta AK; Billes SK; Burns C; Kim D; Dunayevich E; Greenway FL
    Diabetes Obes Metab; 2013 Sep; 15(9):863-6. PubMed ID: 23489381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.
    Hollander P; Gupta AK; Plodkowski R; Greenway F; Bays H; Burns C; Klassen P; Fujioka K;
    Diabetes Care; 2013 Dec; 36(12):4022-9. PubMed ID: 24144653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy.
    Milano W; De Biasio V; Di Munzio W; Foggia G; Capasso A
    Endocr Metab Immune Disord Drug Targets; 2020; 20(8):1232-1243. PubMed ID: 32410565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ACS chemical neuroscience molecule spotlight on contrave.
    Mercer SL
    ACS Chem Neurosci; 2011 Sep; 2(9):484-6. PubMed ID: 22860172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR.
    Drugs R D; 2010; 10(1):25-32. PubMed ID: 20509712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes.
    Hong K; Herrmann K; Dybala C; Halseth AE; Lam H; Foreyt JP
    Clin Obes; 2016 Oct; 6(5):305-12. PubMed ID: 27477337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination?
    Citrome L
    Int J Clin Pract; 2010 Oct; 64(11):1462-1465. PubMed ID: 20846190
    [No Abstract]   [Full Text] [Related]  

  • 34. Naltrexone/bupropion: an investigational combination for weight loss and maintenance.
    Makowski CT; Gwinn KM; Hurren KM
    Obes Facts; 2011; 4(6):489-94. PubMed ID: 22249001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gender-related issues in the pharmacology of new anti-obesity drugs.
    Cataldi M; Muscogiuri G; Savastano S; Barrea L; Guida B; Taglialatela M; Colao A
    Obes Rev; 2019 Mar; 20(3):375-384. PubMed ID: 30589980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.
    Greenway FL; Dunayevich E; Tollefson G; Erickson J; Guttadauria M; Fujioka K; Cowley MA;
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4898-906. PubMed ID: 19846734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current and emerging medications for overweight or obesity in people with comorbidities.
    Fujioka K
    Diabetes Obes Metab; 2015 Nov; 17(11):1021-32. PubMed ID: 26040215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis.
    Pi-Sunyer X; Apovian CM; McElroy SL; Dunayevich E; Acevedo LM; Greenway FL
    Int J Obes (Lond); 2019 Oct; 43(10):2085-2094. PubMed ID: 30664661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Verpeut JL; Bello NT
    Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.